Indication: Breast Cancer
NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Ne
Drug Study
Principal Investigator: Jeffrey Hargis, M.D.Norton Cancer Institute
Sponsor: NRG Oncology
Learn more at ClinicalTrials.gov
Email for more information: Breast-NCIResearch@nortonhealthcare.org
